Clinical Overview
Amisulpride is an atypical antipsychotic with selective dopamine D2/D3 receptor antagonism, primarily available in European markets. It is indicated for schizophrenia and has a unique dose-dependent mechanism where low doses preferentially block presynaptic autoreceptors (potentially improving negative symptoms) while higher doses block postsynaptic receptors (treating positive symptoms).
Primary Clinical Applications
Amisulpride is indicated for acute and chronic schizophrenia, with particular efficacy for both positive and negative symptoms. Its dose-dependent mechanism makes it versatile for different phases of schizophrenia treatment. It may also be used off-label for dysthymia and treatment-resistant depression in some countries.
Mechanism and Clinical Benefits
Amisulpride selectively blocks dopamine D2 and D3 receptors without significant activity at other neurotransmitter systems. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, potentially enhancing dopamine release and improving negative symptoms. At higher doses (400-1200 mg), it blocks postsynaptic receptors, providing antipsychotic effects for positive symptoms.
Clinical Considerations
The medication has minimal anticholinergic, antihistaminergic, or alpha-adrenergic effects, resulting in fewer side effects compared to many other antipsychotics. However, it can cause dose-related prolactin elevation and QT prolongation. It is not metabolized by the liver and is eliminated unchanged by the kidneys, requiring dose adjustment in renal impairment.
Prescribing Information
Dosing & Administration
Schizophrenia – Acute Psychotic Episodes:
- Initial: 400-800 mg daily in divided doses
- Range: 400-1200 mg daily
- Maximum: 1200 mg daily
Schizophrenia – Predominantly Negative Symptoms:
- Dose: 50-300 mg daily
- Optimal range: 100-200 mg daily
Maintenance Therapy:
- Range: 100-600 mg daily
- Adjust based on symptom control and tolerability
Administration:
- May take with or without food
- Divide doses >300 mg into twice daily dosing
- Lower doses may be given once daily
Indications
- Treatment of schizophrenia (acute and chronic)
- Off-label: Dysthymia, treatment-resistant depression (in some countries)
Contraindications
- Hypersensitivity to amisulpride
- Prolactin-dependent tumors (prolactinoma, breast cancer)
- Pheochromocytoma
- Concomitant use with levodopa
- Severe renal impairment (CrCl <10 mL/min)
Warnings & Precautions
- QT prolongation: Dose-dependent risk, monitor ECG in predisposed patients
- Hyperprolactinemia: Dose-related, monitor prolactin levels
- Neuroleptic malignant syndrome: Rare but serious risk
- Tardive dyskinesia: Risk with long-term use
- Venous thromboembolism: Increased risk with antipsychotics
- Hyperglycemia: Monitor glucose in diabetic patients
Drug Interactions
- QT-prolonging drugs: Additive QT prolongation risk
- Levodopa: Contraindicated – mutual antagonism
- CNS depressants: Enhanced sedation
- Antihypertensives: Enhanced hypotensive effects
Adverse Reactions
Common (>10%):
- Insomnia, anxiety, agitation, somnolence
- Extrapyramidal symptoms (dose-related)
Endocrine:
- Hyperprolactinemia, galactorrhea, amenorrhea
- Weight gain (generally modest)
Serious:
- QT prolongation, neuroleptic malignant syndrome
- Tardive dyskinesia, venous thromboembolism
Special Populations
- Renal Impairment: Mild-moderate: reduce dose by 50%; Severe: contraindicated
- Hepatic Impairment: No dose adjustment needed (not hepatically metabolized)
- Elderly: Start with lower doses, monitor for orthostatic hypotension
- Pregnancy: Category C – use only if benefits outweigh risks
- Prolactin monitoring: Regular assessment for hyperprolactinemia
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
